Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a narrative review summarizing existing knowledge about complement C5a receptors in cancer, with limited new primary data on urothelial carcinoma; it raises mechanistic questions rather than reporting a rigorous empirical result.
Novel reagent validation in porcine cells and PBMCs showing CD69 detection capacity and early activation kinetics, but lacks clinical efficacy data, comparative validation against gold standards, or multi-site reproducibility.